Metabolomic Profiling of Cholesterol Efflux Capacity in a Multiethnic Population : Insights From MESA
BACKGROUND: Impaired cholesterol efflux capacity (CEC) is a novel lipid metabolism trait associated with atherosclerotic cardiovascular disease. Mechanisms underlying CEC variation are unknown. We evaluated associations of circulating metabolites with CEC to advance understanding of metabolic pathways involved in cholesterol efflux regulation.
METHODS: Participants enrolled in the MESA (Multi-Ethnic Study of Atherosclerosis) who underwent nuclear magnetic resonance metabolome profiling and CEC measurement (N=3543) at baseline were included. Metabolite associations with CEC were evaluated using standard linear regression analyses. Repeated ElasticNet and multilayer perceptron regression were used to assess metabolite profile predictive performance for CEC. Features important for CEC prediction were identified using Shapley Additive Explanations values.
RESULTS: Greater CEC was significantly associated with metabolite clusters composed of the largest-sized particle subclasses of VLDL (very-low-density lipoprotein) and HDL (high-density lipoprotein), as well as their constituent apo A1, apo A2, phospholipid, and cholesterol components (β=0.072-0.081; P<0.001). Metabolite profiles had poor accuracy for predicting in vitro CEC in linear and nonlinear analyses (R2<0.02; Spearman ρ<0.18). The most important feature for CEC prediction was race, with Black participants having significantly lower CEC compared with other races.
CONCLUSIONS: We identified independent associations among CEC, the largest-sized particle subclasses of VLDL and HDL, and their constituent apolipoproteins and lipids. A large proportion of variation in CEC remained unexplained by metabolites and traditional clinical risk factors, supporting further investigation into genomic, proteomic, and phospholipidomic determinants of CEC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Arteriosclerosis, thrombosis, and vascular biology - 43(2023), 10 vom: 04. Okt., Seite 2030-2041 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hunter, Wynn G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.09.2023 Date Revised 06.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/ATVBAHA.122.318222 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361135130 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361135130 | ||
| 003 | DE-627 | ||
| 005 | 20240306232357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/ATVBAHA.122.318222 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM361135130 | ||
| 035 | |a (NLM)37615111 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hunter, Wynn G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolomic Profiling of Cholesterol Efflux Capacity in a Multiethnic Population |b Insights From MESA |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2023 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Impaired cholesterol efflux capacity (CEC) is a novel lipid metabolism trait associated with atherosclerotic cardiovascular disease. Mechanisms underlying CEC variation are unknown. We evaluated associations of circulating metabolites with CEC to advance understanding of metabolic pathways involved in cholesterol efflux regulation | ||
| 520 | |a METHODS: Participants enrolled in the MESA (Multi-Ethnic Study of Atherosclerosis) who underwent nuclear magnetic resonance metabolome profiling and CEC measurement (N=3543) at baseline were included. Metabolite associations with CEC were evaluated using standard linear regression analyses. Repeated ElasticNet and multilayer perceptron regression were used to assess metabolite profile predictive performance for CEC. Features important for CEC prediction were identified using Shapley Additive Explanations values | ||
| 520 | |a RESULTS: Greater CEC was significantly associated with metabolite clusters composed of the largest-sized particle subclasses of VLDL (very-low-density lipoprotein) and HDL (high-density lipoprotein), as well as their constituent apo A1, apo A2, phospholipid, and cholesterol components (β=0.072-0.081; P<0.001). Metabolite profiles had poor accuracy for predicting in vitro CEC in linear and nonlinear analyses (R2<0.02; Spearman ρ<0.18). The most important feature for CEC prediction was race, with Black participants having significantly lower CEC compared with other races | ||
| 520 | |a CONCLUSIONS: We identified independent associations among CEC, the largest-sized particle subclasses of VLDL and HDL, and their constituent apolipoproteins and lipids. A large proportion of variation in CEC remained unexplained by metabolites and traditional clinical risk factors, supporting further investigation into genomic, proteomic, and phospholipidomic determinants of CEC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a apolipoproteins | |
| 650 | 4 | |a cardiovascular diseases | |
| 650 | 4 | |a cholesterol | |
| 650 | 4 | |a lipids | |
| 650 | 4 | |a lipoproteins | |
| 650 | 7 | |a Cholesterol, HDL |2 NLM | |
| 650 | 7 | |a Lipoproteins, HDL |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 650 | 7 | |a Apolipoproteins A |2 NLM | |
| 700 | 1 | |a Smith, Alexander G |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Rui C |e verfasserin |4 aut | |
| 700 | 1 | |a Saldanha, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Gangwar, Anamika |e verfasserin |4 aut | |
| 700 | 1 | |a Pahlavani, Mandana |e verfasserin |4 aut | |
| 700 | 1 | |a Deodhar, Sneha |e verfasserin |4 aut | |
| 700 | 1 | |a Wilkins, John |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Ambarish |e verfasserin |4 aut | |
| 700 | 1 | |a Herrington, David |e verfasserin |4 aut | |
| 700 | 1 | |a Greenland, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Tzoulaki, Ioanna |e verfasserin |4 aut | |
| 700 | 1 | |a Rohatgi, Anand |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arteriosclerosis, thrombosis, and vascular biology |d 1995 |g 43(2023), 10 vom: 04. Okt., Seite 2030-2041 |w (DE-627)NLM074658522 |x 1524-4636 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:10 |g day:04 |g month:10 |g pages:2030-2041 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/ATVBAHA.122.318222 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 10 |b 04 |c 10 |h 2030-2041 | ||